MBX
MBX Biosciences·NASDAQ
--
--(--)
--
--(--)
MBX fundamentals
During Q4 2025, MBX Biosciences (MBX) reported revenue of --, a YoY change of 0.00%. Net income was -22.06M, a YoY change of -41.55%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 10.95M -- | 9.99M -- | 13.31M -- | 16.66M -- | 19.61M +79.19% | 18.61M +86.27% | 26.53M +99.26% | 21.80M +30.90% | 23.93M +22.00% | 25.80M +38.61% | 98.06M -- |
Selling, General and Administrative Expenses | 1.87M -- | 2.26M -- | 2.27M -- | 2.26M -- | 2.87M +53.04% | 3.39M +49.60% | 4.12M +82.08% | 4.08M +80.42% | 4.66M +62.51% | 6.04M +78.21% | 18.90M -- |
General and Administrative Expenses | 1.87M -- | 2.26M -- | 2.27M -- | 2.26M -- | 2.87M +53.04% | 3.39M +49.60% | 4.12M +82.08% | 4.08M +80.42% | 4.66M +62.51% | 6.04M +78.21% | 18.90M -- |
Research and Development Expenses | 9.07M -- | 7.73M -- | 11.05M -- | 14.40M -- | 16.75M +84.58% | 15.22M +97.01% | 22.41M +102.78% | 17.72M +23.12% | 19.27M +15.07% | 19.76M +29.80% | 79.16M -- |
Operating Income | -10.95M -- | -9.99M -- | -13.31M -- | -16.66M -- | -19.61M -79.19% | -18.61M -86.27% | -26.53M -99.26% | -21.80M -30.90% | -23.93M -22.00% | -25.80M -38.61% | -98.06M -- |
Non-Operating Income (Loss) | 783.00K -- | 1.15M -- | 977.00K -- | 801.00K -- | 1.47M +87.74% | 3.02M +163.41% | 2.65M +171.14% | 2.39M +198.88% | 2.31M +57.01% | 3.73M +23.45% | 11.08M -- |
Net Interest Expense | -783.00K -- | -1.15M -- | -977.00K -- | -801.00K -- | -1.47M -87.74% | -3.02M -163.41% | -2.65M -171.14% | -2.39M -198.88% | -2.31M -57.01% | -3.73M -23.45% | -11.08M -- |
Pretax Income From Continuing Operations | -10.16M -- | -8.84M -- | -12.34M -- | -15.86M -- | -18.14M -78.53% | -15.59M -76.25% | -23.88M -93.56% | -19.41M -22.41% | -21.62M -19.16% | -22.06M -41.55% | -86.97M -- |
Net Income | -10.16M -- | -8.84M -- | -12.34M -- | -15.86M -- | -18.14M -78.53% | -15.59M -76.25% | -23.88M -93.56% | -19.41M -22.41% | -21.62M -19.16% | -22.06M -41.55% | -86.97M -- |
Net Income Attributable to Owners of the Company | -10.16M -- | -8.84M -- | -12.34M -- | -15.86M -- | -18.14M -78.53% | -15.59M -76.25% | -23.88M -93.56% | -19.41M -22.41% | -21.62M -19.16% | -22.06M -41.55% | -86.97M -- |
Net Income Attributable to Common Stockholders | -10.16M -- | -8.84M -- | -12.34M -- | -15.86M -- | -18.14M -78.53% | -15.59M -76.25% | -23.88M -93.56% | -19.41M -22.41% | -21.62M -19.16% | -22.06M -41.55% | -86.97M -- |
Other Comprehensive Income | 9.00K -- | 51.00K -- | -63.00K -- | -12.00K -- | 121.00K +1244.44% | -51.00K -200.00% | -2.00K +96.83% | -42.00K -250.00% | 143.00K +18.18% | 132.00K +358.82% | 231.00K -- |
Total Comprehensive Income | -10.15M -- | -8.79M -- | -12.40M -- | -15.87M -- | -18.02M -77.49% | -15.64M -77.85% | -23.88M -92.60% | -19.45M -22.58% | -21.48M -19.17% | -21.93M -40.24% | -86.74M -- |
Total Comprehensive Income Attributable to Owners of the Company | -10.15M -- | -8.79M -- | -12.40M -- | -15.87M -- | -18.02M -77.49% | -15.64M -77.85% | -23.88M -92.60% | -19.45M -22.58% | -21.48M -19.17% | -21.93M -40.24% | -86.74M -- |
Basic EPS | -9.4 -- | -- -- | -10.26 -- | -12.62 -- | -2.78 +70.43% | -0.47 -- | -0.71 +93.08% | -0.58 +95.40% | -0.63 +77.34% | -0.49 -4.26% | -2.41 -- |
Basic EPS from Continuing Operations | -9.4 -- | -- -- | -10.26 -- | -12.62 -- | -2.78 +70.43% | -- -- | -0.71 +93.08% | -0.58 +95.40% | -0.63 +77.34% | -- -- | -- -- |
Diluted EPS | -9.4 -- | -- -- | -10.26 -- | -12.62 -- | -2.78 +70.43% | -- -- | -0.71 +93.08% | -0.58 +95.40% | -0.63 +77.34% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -9.4 -- | -- -- | -10.26 -- | -12.62 -- | -2.78 +70.43% | -- -- | -0.71 +93.08% | -0.58 +95.40% | -0.63 +77.34% | -- -- | -- -- |
You can ask Aime
What were the key takeaways from MBX Biosciences's earnings call?What does MBX Biosciences do and what are its main business segments?What is MBX Biosciences's latest dividend and current dividend yield?What is the revenue and EPS growth rate for MBX Biosciences year over year?What is MBX Biosciences's gross profit margin?What guidance did MBX Biosciences's management provide for the next earnings period?What factors drove the changes in MBX Biosciences's revenue and profit?Did MBX Biosciences beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
